Severe psoriasis flare after anti-programmed death ligand 1 (PD-L1) therapy for metastatic non-small cell lung cancer (NSCLC)

Journal of Immunotherapy

Volumn 39, Issue 5, 2016, Pages 202-204

  Chia, Puey Ling ^a,b   John, Thomas ^a,b,c  

^a AUSTIN HEALTH   (Australia)

^b OLIVIA NEWTON JOHN CANCER RESEARCH INSTITUTE   (Australia)

^c LA TROBE UNIVERSITY   (Australia)

Author keywords

Autoimmune disease; Immunotherapy; Psoriasis flare

Indexed keywords

AFATINIB; BETAMETHASONE DIPROPIONATE PLUS CALCIPOTRIOL; CARBOPLATIN; GEMCITABINE; MOMETASONE FUROATE; PEMBROLIZUMAB; PROGRAMMED DEATH 1 LIGAND 1; PROGRAMMED DEATH 1 RECEPTOR; ANTINEOPLASTIC AGENT; CALCIPOTRIOL; CALCITRIOL; EPIDERMAL GROWTH FACTOR RECEPTOR; MONOCLONAL ANTIBODY;

AGED; ARTICLE; AUTOIMMUNITY; CANCER IMMUNOTHERAPY; CANCER PATIENT; CASE REPORT; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG SUBSTITUTION; HUMAN; HUMAN TISSUE; LUNG METASTASIS; MALE; MULTIPLE CYCLE TREATMENT; NON SMALL CELL LUNG CANCER; PHOTOTHERAPY; PLEURA DISEASE; PRIORITY JOURNAL; PSORIASIS; PUNCH BIOPSY; STEROID THERAPY; SYSTEMIC THERAPY; TREATMENT RESPONSE; ADENOCARCINOMA; ANALOGS AND DERIVATIVES; EXON; GENE DELETION; GENETICS; IMMUNOLOGY; METASTASIS; PATHOLOGY; SMOKING;

ADENOCARCINOMA; AGED; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; B7-H1 ANTIGEN; CALCITRIOL; CARCINOMA, NON-SMALL-CELL LUNG; CIGARETTE SMOKING; DISEASE PROGRESSION; EXONS; HUMANS; MALE; MOMETASONE FUROATE; NEOPLASM METASTASIS; PHOTOTHERAPY; PSORIASIS; RECEPTOR, EPIDERMAL GROWTH FACTOR; SEQUENCE DELETION;

EID: 84971324112     PISSN: 15249557     EISSN: 15374513     Source Type: Journal    
DOI: 10.1097/CJI.0000000000000121     Document Type: Article

References (15)

1. Gedye C, Van der Westhuizen A, John T. Checkpoint immunotherapy for cancer: superior survival, unaccustomed toxicities. Intern Med J. 2015;45:696-701.
2. Robert C, Schachter J, Long GV, et al. Pembrolizumab versus ipilimumab in advanced melanoma. N Engl J Med. 2015;372: 2521-2532.
3. Weber JS, Kahler KC, Hauschild A. Management of immune-related adverse events and kinetics of response with ipilimu-mab. J Clin Oncol. 2012;30:2691-2697.
4. Gangadhar TC, Vonderheide RH. Mitigating the toxic effects of anticancer immunotherapy. Nat Rev Clin Oncol. 2014;11: 91-99.
5. Abrams JR, Kelley SL, Hayes E, et al. Blockade of T lymphocyte costimulation with cytotoxic T lymphocyte-associated antigen 4-immunoglobulin (CTLA4Ig) reverses the cellular pathology of psoriatic plaques, including the activation of keratinocytes, dendritic cells, and endothelial cells. J Exp Med. 2000;192:681-694.
6. Baker BS, Swain AF, Griffiths CE, et al. Epidermal T lymphocytes and dendritic cells in chronic plaque psoriasis: the effects of PUVA treatment. Clin Exp Immunol. 1985;61:526-534.
7. Gottlieb AB. Immunologic mechanisms in psoriasis. J Invest Dermatol. 1990;95(suppl):18S-19S.
8. Lynde CW, Poulin Y, Vender R, et al. Interleukin 17A: toward a new understanding of psoriasis pathogenesis. J Am Acad Dermatol. 2014;71:141-150.
9. Garon EB, Rizvi NA, Hui R, et al. Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med. 2015;372:2018-2028.
10. Brahmer J, Reckamp KL, Baas P, et al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med. 2015;373:123-135.
11. Weber JS, Yang JC, Atkins MB, et al. Toxicities of immunotherapy for the practitioner. J Clin Oncol. 2015;33: 2092-2099.
12. Kyi C, Carvajal RD, Wolchok JD, et al. Ipilimumab in patients with melanoma and autoimmune disease. J Immunother Cancer. 2014;2:35.
13. Pedersen M, Andersen R, Norgaard P, et al. Successful treatment with ipilimumab and interleukin-2 in two patients with metastatic melanoma and systemic autoimmune disease. Cancer Immunol Immunother. 2014;63:1341-1346.
14. Dulos J, Carven GJ, Van Boxtel SJ, et al. PD-1 blockade augments Th1 and Th17 and suppresses Th2 responses in peripheral blood from patients with prostate and advanced melanoma cancer. J Immunother. 2012;35:169-178.
15. Matsumura N, Ohtsuka M, Kikuchi N, et al. Exacerbation of psoriasis during nivolumab therapy for metastatic melanoma. Acta Derm Venereol. 2015;96:259-260.